

**Melior Discovery:  
An Emerging Biopharmaceutical Company  
Poised to Weather These Uncertain Times**

*Andrew Reaume  
President & CEO  
Melior Discovery, Inc.*


# Melior Discovery: Overview

- Dedicated to drug repositioning
- Proprietary *in vivo* platform (*theraTRACE*®)
  - Unique “high throughput” pharmacology approach
- Unmatched capability to identify best repositioning candidates
- Significant successes to date:
  - Rapid Proprietary pipeline development
  - Multiple, long-term pharma partnerships concluded
    - Pfizer, Johnson & Johnson, Merck, Astra Zeneca, Abbott

# Melior's Business Model as it relates to *Today's* Environment

- A business model that balances internal pipeline of compounds with selected collaborations to provide a revenue stream for operations
  - Company has maintained cash flow break-even while advancing a product pipeline
  - High capital efficiency
    - As regards total raised vs. clinical stage of candidates

# Melior's Drug Pipeline



# MLR-1023 Target Product Profile

- ✓ Once daily, oral route of administration
- ✓ Gold standard glucose lowering when used as monotherapy
- ✓ Superior to sulfonylureas with no risk of hypoglycemia
- ✓ Superior to thiazolidinediones and sulfonylureas with neutral effect on weight
- ✓ Potential disease modification with  $\beta$ -cell sparing / improvement in  $\beta$ -cell function
- ✓ Broad combination use/products with metformin, thiazolidinediones, DPP-IV inhibitors and sulfonylureas
- ✓ Favorable safety and tolerability profile (minimal to mild AEs at projected clinical dose. eg. headache)